Langerhans cell histiocytosis epidemiology and demographics: Difference between revisions
Nawal Muazam (talk | contribs) No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Langerhans cell histiocytosis}} | {{Langerhans cell histiocytosis}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{HL}} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 15:28, 4 February 2016
Langerhans cell histiocytosis Microchapters |
Differentiating Langerhans cell histiocytosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Langerhans cell histiocytosis epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Langerhans cell histiocytosis epidemiology and demographics |
FDA on Langerhans cell histiocytosis epidemiology and demographics |
on Langerhans cell histiocytosis epidemiology and demographics |
Langerhans cell histiocytosis epidemiology and demographics in the news |
Blogs on Langerhans cell histiocytosis epidemiology and demographics |
Directions to Hospitals Treating Langerhans cell histiocytosis |
Risk calculators and risk factors for Langerhans cell histiocytosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]